Skip to content

Drug interactions

Brexucabtagene autoleucel + Certolizumab pegol

Severity: Major

Brexucabtagene autoleucel and Certolizumab pegol: major interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Certolizumab pegol blocks TNF and causes immunosuppression, while brexucabtagene autoleucel is given after lymphodepleting chemotherapy and causes prolonged cytopenias and B-cell aplasia. Together they may raise the risk of serious infection. TNF inhibition may also interfere with CAR-T expansion and cytokine biology.

What this interaction means in plain words

Brexucabtagene autoleucel and Certolizumab pegol can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.

Brexucabtagene autoleucel belongs to Oncology; Certolizumab pegol belongs to Musculoskeletal.

Evidence level: Low

Why it happens

Additive immunosuppression from TNF blockade and CAR-T related lymphodepletion and B-cell aplasia.

What to do

Avoid starting certolizumab pegol around CAR-T infusion unless clearly needed, and consider an alternative. If it cannot be avoided, monitor closely for infection and cytopenias.

What to ask your pharmacist

  • Does the benefit of taking both outweigh the risk in my case?
  • Do I need any blood test, ECG or other check while on both?
  • What early warning signs should I watch for, and what should I do if they appear?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Brexucabtagene autoleucel and Certolizumab pegol, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 7 days on the web. No card needed.

Frequently asked questions

Can I take Brexucabtagene autoleucel with Certolizumab pegol?

MediHelp rates the interaction as major. Brexucabtagene autoleucel and Certolizumab pegol can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Certolizumab pegol blocks TNF and causes immunosuppression, while brexucabtagene autoleucel is given after lymphodepleting chemotherapy and causes prolonged cytopenias and B-cell aplasia. Together they may raise the risk of serious infection. TNF inhibition may also interfere with CAR-T expansion and cytokine biology.

How serious is the interaction between Brexucabtagene autoleucel and Certolizumab pegol?

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid starting certolizumab pegol around CAR-T infusion unless clearly needed, and consider an alternative. If it cannot be avoided, monitor closely for infection and cytopenias.

What other medicines interact with Certolizumab pegol?

MediHelp also lists interactions of Certolizumab pegol with, for example, Adenovirus types 4 and 7 live, Bcg intravesical live, Bcg vaccine live. The full list is on the Certolizumab pegol page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in